Clinical grand rounds: Atypical hemolytic uremic syndrome

Kavita S. Hodgkins*, Amy E. Bobrowski, Jerome C. Lane, Craig B. Langman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a rare, lifethreatening, chronic, genetic disease of uncontrolled alternative pathway complement activation. The understanding of the pathophysiology and genetics of this disease has expanded over recent decades and promising new developments in the management of aHUS have emerged. Regardless of the cause of aHUS, with or without a demonstrated mutation or autoantibody, blockade of terminal complement activation through C5 is of high interest as a mechanism to ameliorate the disease. Eculizumab, an existing monoclonal antibody directed against C5 with high affinity, prevents the perpetuation of the downstream activation of the complement cascade and the damage caused by generation of the anaphylotoxin C5a and the membrane attack complex C5b-9, by blocking C5 cleavage. We report the successful use of eculizumab in a patient after kidney transplantation and discuss the disease aHUS.

Original languageEnglish (US)
Pages (from-to)394-400
Number of pages7
JournalAmerican Journal of Nephrology
Volume35
Issue number5
DOIs
StatePublished - May 2012

Keywords

  • Acute kidney injury
  • Alternative complement pathway
  • Complement factor H
  • Eculizumab
  • Kidney transplant
  • Pediatrics
  • Thrombotic microangiopathy

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Clinical grand rounds: Atypical hemolytic uremic syndrome'. Together they form a unique fingerprint.

Cite this